{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:59:50Z","timestamp":1762433990703,"version":"build-2065373602"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Japanese encephalitis is a severe mosquito-borne disease requiring effective prevention and ongoing vaccine safety monitoring. This study aimed to analyze the characteristics, severity, and reporting trends of adverse events associated with Japanese encephalitis vaccines (JEV) in the U. S. Vaccine Adverse Event Reporting System (VAERS). We also investigated the correlation between Google search trends and adverse event reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were extracted from VAERS (1993\u20132025). Descriptive statistics, including demographics and temporal trends, were performed. Disproportionality analysis used the reporting odds ratio (ROR) with a 95% confidence interval (CI). Google Trends analysis covered 2004\u20132025 (worldwide, topic: \u201cJapanese Encephalitis Vaccine\u201d).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,384 reports (6,596 vaccine-event pairs) were retrieved. IXIARO accounted for 3,452 pairs, JE-VAX 1368, J-VAX 698, and \u201cunspecific Brand\u201d 1,078. Serious reports totaled 284 (20.5%), and fatal reports 11 (0.80%). The 18\u201329 years group comprised 39.52% (\n                      <jats:italic>n<\/jats:italic>\n                      = 547) of reports, while the \u226560 years group constituted 3.4% (\n                      <jats:italic>n<\/jats:italic>\n                      = 47), with no fatal outcomes reported in this demographic. Key disproportionality signals (RORs) included nausea (\n                      <jats:italic>n<\/jats:italic>\n                      = 134, ROR = 1.32), dizziness (\n                      <jats:italic>n<\/jats:italic>\n                      = 132, ROR = 1.33), pruritus (\n                      <jats:italic>n<\/jats:italic>\n                      = 127, ROR = 2.33), and urticaria (\n                      <jats:italic>n<\/jats:italic>\n                      = 122, ROR = 2.89). Noteworthy brand-specific signals: IXIARO (loss of consciousness\n                      <jats:italic>n<\/jats:italic>\n                      = 32, ROR = 2.88; seizure\n                      <jats:italic>n<\/jats:italic>\n                      = 17, ROR = 2.97), JE-VAX (encephalitis\n                      <jats:italic>n<\/jats:italic>\n                      = 5, ROR = 15.69; angioneurotic oedema\n                      <jats:italic>n<\/jats:italic>\n                      = 4, ROR = 68.17), and J-VAX (laryngospasm\n                      <jats:italic>n<\/jats:italic>\n                      = 11, ROR = 185.73). Google search volume showed strong temporal correlation with VAERS reports (2004\u20132025).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study revealed the reporting patterns of JEV vaccine adverse events in the VAERS database, indicating that a considerable proportion of reports were serious events, and allergic reactions such as pruritus, rash, and urticaria were prominent. The observed overlap between spontaneous reporting and online search trends suggests public awareness and information dissemination influence reporting patterns. These findings underscore the need for continued JEV safety surveillance and further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1647485","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:54:52Z","timestamp":1762433692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of Japanese encephalitis vaccines: a comprehensive analysis of vaccine adverse event reports from 1993 to 2025"],"prefix":"10.3389","volume":"13","author":[{"given":"Fujun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qibo","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/v13061154","article-title":"Mosquito vector competence for Japanese encephalitis virus","volume":"13","author":"Auerswald","year":"2021","journal-title":"Viruses"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/13550280591002487","article-title":"Emerging zoonotic encephalitis viruses: lessons from Southeast Asia and Oceania","volume":"11","author":"Mackenzie","year":"2005","journal-title":"J Neurovirol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e0003576","DOI":"10.1371\/journal.pntd.0003576","article-title":"The potential use of Wolbachia-based mosquito biocontrol strategies for Japanese encephalitis","volume":"9","author":"Jeffries","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e0009977","DOI":"10.1371\/journal.pntd.0009977","article-title":"The feasibility of field collected pig oronasal secretions as specimens for the virologic surveillance of Japanese encephalitis virus","volume":"15","author":"Chiou","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1371\/journal.pntd.0000114","article-title":"Measuring the burden of neglected tropical diseases: the global burden of disease framework","volume":"1","author":"Mathers","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40249-019-0608-7","article-title":"Reduction patterns of Japanese encephalitis incidence following vaccine introduction into long-term expanded program on immunization in Yunnan Province, China","volume":"8","author":"Hu","year":"2019","journal-title":"Infect Dis Poverty"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrneurol.2018.30","article-title":"Japanese encephalitis \u2014 the prospects for new treatments","volume":"14","author":"Turtle","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.11604\/pamj.2021.40.81.25910","article-title":"Adverse events following immunization reporting and impact on immunization services in informal settlements in Nairobi, Kenya: a prospective mixed-methods study","volume":"40","author":"Malande","year":"2021","journal-title":"Pan Afr Med J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"20420986221125006","DOI":"10.1177\/20420986221125006","article-title":"Pharmacovigilance: reporting requirements throughout a product\u2019s lifecycle","volume":"13","author":"Lucas","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1016\/S0264-410X(00)00111-0","article-title":"Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States","volume":"18","author":"Takahashi","year":"2000","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1016\/j.vaccine.2018.04.038","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012\u20132016","volume":"36","author":"Walker","year":"2018","journal-title":"Vaccine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/vaccines12020176","article-title":"Vaccine hesitancy and public mistrust during pandemic decline: findings from 2021 and 2023 cross-sectional surveys in northern Italy","volume":"12","author":"Barbieri","year":"2024","journal-title":"Vaccines"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1016\/j.vaccine.2023.06.023","article-title":"Post-authorization safety surveillance of ad.26.COV2.S vaccine: reports to the vaccine adverse event reporting system and v-safe, February 2021\u2013February 2022","volume":"41","author":"Woo","year":"2023","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Safety"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/bcp.13841","article-title":"Safety profile of human papilloma virus vaccines: an analysis of the US vaccine adverse event reporting system from 2007 to 2017","volume":"85","author":"Bonaldo","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40794-015-0013-6","article-title":"Japanese encephalitis: a review of clinical guidelines and vaccine availability in Asia","volume":"1","author":"Batchelor","year":"2015","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"key":"ref21","first-page":"1","article-title":"Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)--United States, 1991-2001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2023.01.061","article-title":"Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011\u2013august 2019","volume":"41","author":"Seshadri","year":"2023","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3349\/ymj.2020.61.7.623","article-title":"Updates on vaccine safety and post-licensure surveillance for adverse events following immunization in South Korea, 2005\u20132017","volume":"61","author":"Yoon","year":"2020","journal-title":"Yonsei Med J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00003495-200969010-00008","article-title":"Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO\u00ae]","volume":"69","author":"Duggan","year":"2009","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese encephalitis vaccine: recommendations of the advisory committee on immunization practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1016\/j.vaccine.2011.11.112","article-title":"Anti-vaccine activists, web 2.0, and the postmodern paradigm \u2013 an overview of tactics and tropes used online by the anti-vaccination movement","volume":"30","author":"Kata","year":"2012","journal-title":"Vaccine"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1647485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:54:52Z","timestamp":1762433692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1647485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":26,"alternative-id":["10.3389\/fpubh.2025.1647485"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1647485","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1647485"}}